logo
Scientists Found 52-Foot-Tall Underground Ripples From the Asteroid That Killed the Dinosaurs

Scientists Found 52-Foot-Tall Underground Ripples From the Asteroid That Killed the Dinosaurs

Yahoo12-03-2025
Some 66 million years after the Chicxulub asteroid impact kickstarted the Cretaceous–Paleogene (K-T) extinction, scientists are still finding stunning evidence of its destruction.
In 2021, researchers spotted 'megaripples' nearly one mile below the surface, suggesting that the megatsunami created by the impact left behind geologic formations as the waves collided with the continental shelf.
Now, the authors have expanded the search and found evidence of megaripples in a 900-square-mile area throughout the Gulf of Mexico, along with their varying formations along the upper shelf and the deep sea.
Of the five mass extinctions that have impacted our planet in the past 500 million years, the Cretaceous–Paleogene (K-T) extinction event certainly delivers on dramatic flair. On a spring day some 66 million years ago, a six-mile-wide asteroid smashed down just north of what is now Mexico's Yucatan Peninsula. This sudden impact created tsunamis stretching one mile tall and racing outward from the asteroid's dino-killing blow. As those waves raced toward present-day Louisiana (which was largely underwater at the time), they achieved most of their gargantuan height as they reached the ramp of the continental shelf.
In 2021, using seismic data gathered by the oil and natural gas company Devon Energy, scientists led by Gary Kinsland from the University of Louisiana at Lafayette found evidence of this geologic trauma in the form of 52-foot-tall 'megaripples' located one mile underground—an area of rock associated with the end-Cretaceous period. Initially surveying a 77-mile area, Kinsland and his team determined that these subterranean ripples likely formed as the asteroid-generated megatsunamis disturbed sediment near the shore.
Now, a new study from the same team reveals that these 'megaripples'—roughly spaced up to one kilometer apart—can be found both further up the shelf of what is now central Louisiana and further down in deeper waters of the Gulf of Mexico. The scientists behind this new paper found evidence of megaripples in a larger, 900-square-mile area, and explain that these formations vary depending on where the tsunami impacted sediments along the paleo-shelf. The results of the study were published in the journal Marine Geology.
'The megaripples are different on the slope, at the shelf break and further up the shelf,' Kinsland, the lead author of the new study, told Live Science. 'This is important information in modeling of tsunami, in prediction of future tsunami interactions with shelves and in the understanding of the Chicxulub tsunami.'
As the study explains, the largest of these megaripples can be seen along the paleo-shelf break—the area where the Gulf's depth dramatically increases down the slope of the continental shelf toward the deep sea. The way that waves interact with the continental shelf is a well-known process known as the 'Van Dorn effect,' which describes how waves surge over a shelf. The study also discovered that megaripples further inland were more weakly asymmetric, suggesting the waves' behavior changed as they entered shallower waters. Conversely, megaripples in the deep sea took on varied shapes, likely as a result of interactions with faults and collapses, according to Live Science.
'From the coverage of the three areas here in Louisiana we infer that the buried northern Gulf of Mexico shelf system, from Texas to Florida, is covered with megaripples from at least the paleo-slope up to the paleo-bathymetry where Gulf storms would have eroded the megaripples after their formation,' the team said in a press statement.
While this gives scientists a better understanding of how the Chicxulub impact tsunami affected the region, it also provides a stunningly powerful example of how tsunamis interact with continental shelves. And if our worst fears are ever realized, it may help us prepare for future asteroid encounters during Earth's never-ending journey through the universe.
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bone-Eating Worms Have Lurked in The Ocean For 100 Million Years
Bone-Eating Worms Have Lurked in The Ocean For 100 Million Years

Yahoo

time2 days ago

  • Yahoo

Bone-Eating Worms Have Lurked in The Ocean For 100 Million Years

Not content with a diet of old leaves, some worm species actually eat bones. A new study has now traced the ancient ancestors of these bone-burrowers back through 100 million years of evolution. Deep in the ocean, bone-eating worms from the genus Osedax feast on the carcasses of whales, sucking up fats and proteins from the skeletons. And it looks like they've been doing so for a while now. By scanning fossils to look for traces of bone-eating behavior, researchers from University College London (UCL) and the Natural History Museum in the UK have been able to identify seven new types of worm from the Cretaceous period. There would've been no whale on the menu at that time, but traces left behind by these worms were found in fossils of mosasaurs, ichthyosaurs, and plesiosaurs: the dominant marine reptiles of the time, now on show in museum exhibits. Related: "We haven't found anything else that makes a similar burrow to these animals," says ‪paleontologist Sarah Jamison-Todd, from UCL. "As the ancient bores are so similar to modern Osedax species, and we don't have body fossils to contradict us, we assume that they were made by the same or a similar organism." "It shows that the bone-eating worms are part of a lineage that stretches back at least to the Cretaceous, and perhaps further. We can see how the diversity of bone-eating worms changes across millions of years." The team was able to build 3D models of 130 fossils without damaging them, through the use of computed tomography (CT) scans. Six fossils showed signs of burrows. That then led to the identification of seven new ichnospecies – species categorized based on traces in fossils, rather than direct remains of the creatures. Some of the boring patterns matched modern-day species, suggesting a surprising level of evolutionary stability across many millions of years. The researchers also used microscopic fragments around the fossils to date the bones and the worms that chewed through them. That placed them at at least 100 million years ago, meaning these creatures evolved much earlier than previously thought. "By using the remains of small organisms that make up the chalk itself, we were able to date the fossils to more precise time slices of the Cretaceous period," says Marc Jones, paleontologist at the Natural History Museum. There are plenty of other discoveries like this still waiting to be made, the researchers suggest – which could happen through further scans of ancient fossils as well as studies of the modern species living in the oceans today. Additional work looking at the genetics of the organisms living today could tell us more about the evolutionary history of these tiny creatures, though researchers will have to collect more samples and more data first. "There are many more examples of boring that haven't yet been named from both ancient and modern bone-eating worms," says Jamison-Todd. "In fact, some bores from the Cretaceous appear to be similar to ones that are still made today." "Finding out whether these burrows are made by the same species, or are an example of convergent evolution, will give us a much better idea of how these animals have evolved, and how they have shaped marine ecosystems over millions of years." The research has been published in PLOS ONE. Related News Ancient Voice Box Finally Reveals How Dinosaurs May Have Sounded Stunning Grand Canyon Fossils Reveal Evolution's Weird Experiments Neither Scales Nor Feathers: Bizarre Appendage Discovered on Reptile Fossil Solve the daily Crossword

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers
ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers

Yahoo

time4 days ago

  • Yahoo

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers

AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell's deep expertise and track record. LONDON & NEW YORK, July 29, 2025--(BUSINESS WIRE)--ViroCell Biologics ("ViroCell"), a specialist viral vector Contract Development and Manufacturing Organisation ("CDMO") for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be used to manufacture AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B cell malignancies and autoimmune diseases. AvenCell's AV203 is its second investigational cell therapy using its differentiated allogeneic engineering to provide an "off-the-shelf" product engineered to overcome graft-versus-host disease as well as graft rejection by host T and Natural Killer ("NK") cells. AVC-203 is designed to achieve superior efficacy compared to currently-approved CAR-Ts while enabling immediate treatment and greater patient access at much lower cost and complexity. The further inclusion of AvenCell's RevCAR™ receptor in AVC203 allows for additional antigen targeting (with "off/on" capability in vivo) beyond CD19 and CD20. AvenCell selected ViroCell as its partner to manufacture the retroviral vector for this program based on the CDMO's expertise and track record in delivering high yield vectors at speed. Incorporating a cell line acquired by AvenCell into the GMP manufacturing process, ViroCell successfully delivered a high yield vector while meeting AvenCell's accelerated timeline. This program evidences ViroCell's ability to deliver a bespoke, complex manufacturing process in the allogeneic CAR-T cell therapy space, ultimately, enabling AvenCell's timelines for clinical entry. AvenCell's AVC-203 is expected to enter a first-in-human phase I study in patients with relapsed/refractory B cell lymphoma in H2/2025. John W. Hadden II, CEO of ViroCell, commented: "We are thrilled to partner with AvenCell and support their innovative allogeneic CAR-T therapy platform. I am proud of Team ViroCell's accomplishments on the successful end-to-end delivery of this retroviral vector and accelerating a novel therapy into clinical development in an area of high unmet need. We look forward to continuing our work with AvenCell on their exciting platform." Andrew Schiermeier, Ph.D., CEO, AvenCell, added: "We are delighted with ViroCell's performance in process development and GMP manufacture of this complex retroviral vector. We selected ViroCell to support our platform because we knew that they could execute reliably in areas where other CDMOs can't. The delivery of this retroviral vector for AVC-203 is proof that our trust in ViroCell was well placed." Notes to editor: ViroCell ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization ("CDMO") focused exclusively on the design, de-risking, and GMP manufacture of viral vectors for clinical trials. Built around one of the most prolific academic viral vector manufacturing teams, ViroCell was created to address the global demand for precisely engineered viral vectors. The team leverages its deep track record to help clients to de-risk and accelerate novel cell and gene therapies into and through clinical development, with a mission of being the partner of choice for corporate and academic innovators. Focused initially on manufacturing lentiviral and retroviral vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk. AvenCell Therapeutics AvenCell derives its name from the French word "avenir" to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches. AvenCell Therapeutics, Inc. was launched in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics. AvenCell is headquartered in Watertown, Massachusetts with additional R&D and manufacturing operations in Dresden, Germany. View source version on Contacts For more information, please contact: ViroCell John W. Hadden II, CEOinfo@ For media enquiries, please contact: ViroCell – FTI Consulting Simon Conway / Tim StamperViroCell@ +44 (0)20 3727 1000 AvenCell – H Advisors Emma +1 (917) 763-6685 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore
Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore

Yahoo

time5 days ago

  • Yahoo

Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore

Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers. CAR-T cell therapy is a form of immunotherapy that is currently only approved for use to treat blood cancers, such as certain types of lymphomas and multiple myeloma. As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, to drive the development of next-generation cell therapies. These technologies are already being investigated in Elpis' global clinical trials of EPC-002 and EPC-003, with the goal of expanding their translational relevance across multiple tumor types. Plans are also underway for Elpis to establish a laboratory space at NCCS and co-share its equipment to enable more integrated and efficient collaboration. "This partnership reflects our commitment to rapidly advancing innovative immunotherapies from discovery to clinical development through to regulatory review and, hopefully saving patients' lives," said Yan Chen, MD, PhD, Founder and CEO of Elpis Biopharmaceuticals. "By combining Elpis's proprietary technology with NCCS's clinical expertise, we look forward to accelerating the delivery of these potential groundbreaking new cancer therapies to patients in Singapore and beyond." NCCS will contribute its expertise in clinical research and access to clinical trial infrastructure to support the evaluation of novel cell therapy candidates. "The potential of using cell therapies for solid tumors is still being explored, and this collaboration will enable us to evaluate promising new technologies in a clinical context to address current unmet needs and improve patient outcomes," said Professor Lim Soon Thye, CEO of NCCS. "This is a key collaboration with NCCS' precision immunotherapy program. With our respective strengths and the shared goal of transforming clinical care through translational science, we look forward to offering clinical trials and developing novel cell therapies to better meet the needs of patients in Singapore and the region," added Professor Daniel Tan, Head, Division of Clinical Trials and Epidemiological Sciences and Senior Consultant, NCCS. The collaboration will support the development of bispecific armored CAR-T cell therapies for solid tumors, while Elpis's global leading mRNA display technology will support NCCS in the rapid discovery of human antibodies to novel targets and enable novel modalities to cell therapy and beyond. "The MOU represents an expansion of Elpis's living drug strategy and a key step toward enabling broader clinical translation of our cutting-edge cell therapy technologies," said Chee-Yong Lim, Co-Founder, Co-CEO & Chief Strategy Officer, Elpis Biopharmaceuticals. "Together, we are working to make living drugs a reality for patients with cancers that currently lack effective treatment options." About Elpis Biopharmaceuticals Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation cell therapies for the treatment of solid tumors. The company is advancing a pipeline of first- and best-in-class bispecific armored CAR-T therapies designed to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment. Its proprietary platforms—including a multi-mechanism armor technology, bispecific targeting antibodies, a cytokine cocktail-based cell manufacturing process, and a rapid mRNA display discovery engine—are integrated to deliver safer, more durable, and more effective therapeutic responses. Elpis's lead programs include EPC-003 for glioblastoma and EPC-002 for a broad range of solid tumors. Elpis Biopharmaceuticals is headquartered in Singapore and Boston, MA. For more information, visit Contact Tiberend Strategic Advisors, Inc. Jonathan Nugent (investors) +1-205-566-3026 jnugent@ Eric Reiss (media) ereiss@ View original content: SOURCE Elpis Biopharmaceuticals Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store